Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2

Nature

Volumn 490, Issue 7420, 2012, Pages 417-420

  Rolland, Morgane ^a   Edlefsen, Paul T ^b   Larsen, Brendan B ^c   Tovanabutra, Sodsai ^a   Sanders Buell, Eric ^a   Hertz, Tomer ^b   Decamp, Allan C ^b   Carrico, Chris ^d,e   Menis, Sergey ^d,e   Magaret, Craig A ^b   Ahmed, Hasan ^b   Juraska, Michal ^b   Chen, Lennie ^c   Konopa, Philip ^c   Nariya, Snehal ^c   Stoddard, Julia N ^c   Wong, Kim ^c   Zhao, Hong ^c   Deng, Wenjie ^c   Maust, Brandon S ^c   Bose, Meera ^a   Howell, Shana ^a   Bates, Adam ^a   Lazzaro, Michelle ^a   O'Sullivan, Annemarie ^a   Lei, Esther ^a   Bradfield, Andrea ^a   Ibitamuno, Grace ^a   Assawadarachai, Vatcharain ^a   O'Connell, Robert J ^a   Desouza, Mark S ^a   Nitayaphan, Sorachai ^a   Rerks Ngarm, Supachai ^a   Robb, Merlin L ^a   McLellan, Jason S ^f   Georgiev, Ivelin ^g   Kwong, Peter D ^h   Carlson, Jonathan M ⁱ   Michael, Nelson L ^a   Schief, William R ^d,e   Gilbert, Peter B ^b   Mullins, James I ^c   Kim, Jerome H ^a   more..

^a US Military HIV Research Program   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^e SCRIPPS RESEARCH INSTITUTE   (United States)

^f ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

^g MINISTRY OF PUBLIC HEALTH   (Thailand)

^h NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

ⁱ MICROSOFT RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; PLACEBO; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS ENVELOPE PROTEIN V1; VIRUS ENVELOPE PROTEIN V2;

ANTIBODY; CATION; GENETIC ANALYSIS; GENOME; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; PUBLIC HEALTH; RISK ASSESSMENT; VACCINATION; VACCINE;

ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; GENE SEQUENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; VACCINATION;

AIDS VACCINES; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENETIC PREDISPOSITION TO DISEASE; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; PHYLOGENY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEQUENCE ANALYSIS, DNA;

EID: 84867653590     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature11519     Document Type: Article

References (30)

1. Rerks-Ngarm, S. et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361, 2209-2220 (2009).
2. Haynes, B. F. et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366, 1275-1286 (2012).
3. Plotkin, S. A. & Gilbert, P. B. Nomenclature for immune correlates of protection after vaccination. Clin. Infect. Dis. 54, 1615-1617 (2012).
4. Rolland, M. & Gilbert, P. Evaluating immune correlates in HIV type 1 vaccine efficacy trials: what RV144 may provide. AIDS Res. Hum. Retroviruses 28, 400-404 (2012).
5. Gilbert, P. B., Self, S. G. & Ashby, M. A. Statistical methods for assessing differential vaccine protection against human immunodeficiency virus types. Biometrics 54, 799-814 (1998).
6. Gilbert, P., Self, S., Rao, M., Naficy, A. & Clemens, J. Sieve analysis: methods for assessing from vaccine trial data how vaccine efficacy varies with genotypic and phenotypic pathogen variation. J. Clin. Epidemiol. 54, 68-85 (2001).
7. Rolland, M. et al. Genetic impactof vaccinationonbreakthrough HIV-1 sequences from the STEP trial. Nature Med. 17, 366-371 (2011).
8. Wei, X. et al. Antibody neutralization and escape by HIV-1. Nature 422, 307-312 (2003).
9. Moore, P. L. et al. Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection. PLoS Pathog. 5, e1000598 (2009).
10. Tomaras, G. D. et al. Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals. J. Virol. 85, 11502-11519 (2011).
11. Lynch, R. M. et al. The B cell response is redundant and highly focused on V1V2 during early subtype C infection in a Zambian seroconverter. J. Virol. 85, 905-915 (2011).
12. Robb, M. L. et al. Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144. Lancet Infect. Dis. 12, 531-537 (2012).
13. Gilbert, P. B., Wu, C. & Jobes, D. V. Genome scanning tests for comparing amino acid sequences between groups. Biometrics 64, 198-207 (2008).
14. Edlefsen, P. T. Model-based sieve analysis. Preprint at http://arxiv.org/abs/1206.6701 (2012).
15. Gilbert, P. B. et al. Statistical interpretation ofthe RV144 HIV vaccine efficacy trial in Thailand: a case study for statistical issues in efficacy trials. J. Infect. Dis. 203, 969-975 (2011).
16. Carlson, J. M. et al. Phylogenetic dependency networks: inferring patterns of CTL escape and codon covariation in HIV-1 Gag. PLoS Comput. Biol. 4, e1000225 (2008).
17. Felsenstein, J. Phylogenies and the comparative method. Am. Nat. 125, 1-15 (1985).
18. Pond, S. L. & Frost, S. D. Datamonkey: rapid detection of selective pressure on individual sites of codon alignments. Bioinformatics 21, 2531-2533 (2005).
19. Derdeyn, C. A. et al. Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science 303, 2019-2022 (2004).
20. Moore, P. L. et al. Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targetingaquaternary epitope including residuesintheV2loop. J. Virol. 85, 3128-3141 (2011).
21. Doria-Rose, N. A. et al. Ashort segmentofthe HIV-1gp120 V1/V2regionisamajor determinant of resistance to V1/V2 neutralizing antibodies. J. Virol. 86, 8319-8323 (2012).
22. McLellan, J. S. et al. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 480, 336-343 (2011).
23. Rubinstein, N. D. et al. Computational characterization of B-cell epitopes. Mol. Immunol. 45, 3477-3489 (2008).
24. Gilbert, P. B., Novitsky, V. & Essex, M. Covariability of selected amino acid positions for HIV type 1 subtypes C and B. AIDS Res. Hum. Retroviruses 21, 1016-1030 (2005).
25. Poon, A. F., Lewis, F. I., Pond, S. L. & Frost, S. D. An evolutionary-network model reveals stratified interactions in the V3 loop of the HIV-1 envelope. PLoS Comput. Biol. 3, e231 (2007).
26. Prentice, R. L. et al. The analysis of failure times in the presenceofcompeting risks. Biometrics 34, 541-554 (1978).
27. Lunn, M. & McNeil, D. Applying Cox regression to competing risks. Biometrics 51, 524-532 (1995).
28. Grambsch, P. & Therneau, T. M. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 81, 515-526 (1994).
29. Gilbert, P. B. Comparison of competing risks failure time methods and time-independent methods for assessing strain variations in vaccine protection. Stat. Med. 19, 3065-3086 (2000).
30. Storey, J. D. The positive false discovery rate: a Bayesian interpretation and the q-value. Ann. Stat. 31, 2013-2035 (2003).